Introduction {#sec0001}
============

The natural course of type 2 diabetes is characterized by a progressive deterioration of beta-cell function. Patients need lifelong monitoring and treatment adjustments with subsequent dose intensification to achieve glycemic control.[@bib0001] Patients with type 2 diabetes who do not respond to combination therapy with oral antihyperglycemic drugs (OADs) have traditionally received intensification therapy with basal and rapid-acting insulins. These strategies have been shown to effectively reduce glycosylated haemoglobin (HbA1c) and fasting blood glucose (FBG), but usually result in unwanted side effects such as weight gain and episodes of hypoglycemia.[@bib0002], [@bib0003], [@bib0004]

The current American Diabetes Association and the European Association for the Study of Diabetes consensus statement recommends the addition of glucagon-like peptide-1 (GLP-1) receptor agonist (RA) to basal insulin (combination injectable therapy) as an option to improve metabolic control in patients with type 2 diabetes.[@bib0005] These agents achieve a physiologic blood glucose-insulin response with low risk of hypoglycemia, by mimicking the effect of the endogenous GLP-1 hormone, enhancing insulin secretion and reducing glucagon release.[@bib0006]

Lixisenatide is a once-daily, short-acting GLP-1 RA that is associated with a delay in gastric emptying and, as a result, mediates particularly pronounced reductions in postprandial blood glucose (PPG). It is crucial that PPG, and not only FBG, is adequately controlled to achieve target HbA1c levels and potentially prevent cardiovascular risk. The use of a short-acting GLP-1 RA, such as lixisenatide, targeting predominantly PPG, in combination with a basal insulin, controlling mainly FBG, exploits the complementary effects of both of these therapies.[@bib0007]

Despite a number of clinical studies that have demonstrated effective reductions in HbA1c and blood glucose levels with lixisenatide combined with basal insulin in comparison with placebo,[@bib0008], [@bib0009], [@bib0010] or prandial insulin glulisine,[@bib0011] there are limited data available regarding real-world settings. For this reason, we performed the current retrospective observational study, involving patients with type 2 diabetes who had initiated treatment with lixisenatide in combination with basal insulin due to poor glycemic control in routine clinical practice conditions.

Materials and Methods {#sec0002}
=====================

Study design {#sec0003}
------------

The BASAL-LIXI Study was a retrospective, multicenter study, carried out in 33 endocrinology and internal medicine departments across Spain between October 2014 and May 2015. The study was conducted in accordance with the Declaration of Helsinki, including all amendments, and was approved by the Independent Research Ethics Committee at Hospital Costa del Sol (Málaga, Spain). All patients provided their written informed consent before being included in the study.

Patients {#sec0004}
--------

Eligible patients were all adults with a documented diagnosis of type 2 diabetes who were initiated on lixisenatide treatment in combination with basal insulin (with or without OADs) due to poor glycemic control at least 24 weeks before study inclusion. Those patients with other types of diabetes (eg, type 1 or gestational), severe concomitant diseases, or who had participated in a clinical trial 1 year before the study were excluded. Each investigator selected a maximum of 8 patients who met all the selection criteria and had given their written informed consent.

Study objectives {#sec0005}
----------------

The primary objective was to document the change in HbA1c associated with the addition of lixisenatide to basal insulin (considered as baseline) from baseline to Week 24. Secondary objectives were to determine HbA1c response rates (\<7% and \<6.5%), and changes in FBG level, PPG level, body weight, body mass index (BMI), and daily basal insulin dose. Further objectives were to document the frequency of hypoglycemic events (blood glucose levels \< 70 mg/dL) and adverse drug reactions (ADRs) related to lixisenatide.

Statistical considerations {#sec0006}
--------------------------

A descriptive analysis was carried out on the study variables using measures of central tendency and dispersion for quantitative variables, and valid frequencies and percentages for qualitative variables. When an inferential analysis was required, parametric tests were used for continuous variables and nonparametric tests in the case of ordinal or categorical or nonparametric variables. For variables not fitting a normal (or parametric) distribution, the Mann-Whitney test (for unpaired data) and the Wilcoxon test (paired data) were used. Missing data were not imputed and were left as lost. Statistical analyses were performed using the Statistical Package for the Social Sciences version 17.0 software package (IBM-SPSS Inc, Armonk, NY). All hypothesis tests were 2-sided and with a significance level of 0.05.

Results {#sec0007}
=======

Patient population {#sec0008}
------------------

A total of 134 patients were included in the study. Five patients were excluded due to screening failures. Therefore, the evaluable population comprised 129 patients ([Table 1](#tbl0001){ref-type="table"}). Mean (SD) age was 58.7 (10) years, 52.7% were men, and most patients were obese, with a mean (SD) BMI of 35.8 (5.0). Patients had a mean (SD) diabetes duration of 10.2 (6.4) years and showed mean (SD) HbA1c levels of 8.7% (1.5%).Table 1Patient characteristics at baseline (N = 129).[\*](#tb1fn1){ref-type="table-fn"}Table 1ResultDemographic data Age, y58.7 (10.0) Male sex68 (52.7)Anthropometric data Body weight, kg97.6 (16.3) Body mass index35.8 (5.0) Waist perimeter,[†](#tb1fn2){ref-type="table-fn"} cm112.7 (14.6)Time of diabetes evolution, y10.2 (6.4)Glycemic control parameters Glycated hemoglobin, %8.7 (1.5) Fasting plasma glucose, mg/dL175.4 (58.5) Postprandial glucose[†](#tb1fn2){ref-type="table-fn"} mg/d218.9 (56.2)[^2][^3]

Effectiveness of intensification therapy with lixisenatide {#sec0009}
----------------------------------------------------------

Following 24 weeks of intensification therapy with lixisenatide, a significant reduction of 1.1% (*P* \< 0.001) of the mean HbA1c levels was achieved ([Figure 1](#fig0001){ref-type="fig"}). A significant increase in the percentage of patients achieving HbA1c ≤7.0% (9.3% vs 30.2%; *P* \< 0.001) and HbA1c ≤6.5% (3.1% vs 17.1%; *P* \< 0.001) were also observed. The mean (SD) FBG level decreased significantly by 31.8 (60.3) mg/dL (*P* \< 0.001) (from 175.4 \[58.5\] to 143.5 \[46.7\] mg/dL; *P* \< 0.001) and the PPG level by 55.0 \[49\] mg/dL (*P* \< 0.001) (from 218.9 \[56.2\] to 163.9 \[39.8\] mg/dL; *P* \< 0.001). [(Table 2)](#tbl0002){ref-type="table"}.Figure 1Evolution of glycated hemoglobin (HbA1c) levels following 24 weeks of intensification of basal insulin therapy with lixisenatide.Figure 1.Table 2Evolution of anthropometric data and glycemic control parameters from baseline to Week 24 after intensification therapy with lixisenatide.Table 2Baseline[\*](#tb2fn1){ref-type="table-fn"}Week 24[\*](#tb2fn1){ref-type="table-fn"}*P* valueAnthropometric data Body weight (kg)97.6 (16.3)93.6 (15.7)\< 0.001 Body mass index35.8 (5.0)34.4 (4.9)\< 0.001  Glycemic control parameters Glycated hemoglobin (%)8.7 (1.5)7.6 (1.2)\< 0.001 Fasting plasma glucose (mg/dL)175.4 (58.5)143.5 (46.7)\< 0.001 Postprandial glucose[†](#tb2fn2){ref-type="table-fn"} (mg/d)218.9 (56.2)163.9 (39.8)\< 0.001[^4][^5]

Additionally, mean (SD) body weight decreased 4.0 (5.4) kg (*P* \< 0.001) and the BMI decreased with a mean (SD) difference of 1.5 (1.9) (*P* \< 0.001) (from 35.8 \[5\] to 34.4 \[4.9\]; *P* \< 0.001) (Table). A simultaneous decrease in values of HbA1c and weight was observed in 72.9% of patients at 6 months ([Figure 2](#fig0002){ref-type="fig"}).Figure 2Glycated hemoglobin (HbA1c) and weight changes at 6 months.Figure 2.

Diabetes treatment {#sec0010}
------------------

Most patients (99.2%) initiated lixisenatide at the starting dosage of 10 µg once daily. After 14 days, 128 patients (99.2%) reached the maintenance dosage of 20 µg once daily and only 1 (0.8%) patient maintained 10 µg a day. Six months later, 127 patients (98.4%) continued with the maintenance dosage of 20 µg once daily and 2 patients (1.6%) were taking 10 µg lixisenatide once daily due to nausea.

At baseline, the vast majority of patients (83.7%) were receiving insulin glargine as the basal insulin. The percentage of patients receiving detemir was 10.9%, regular insulin 8.5%, and neutral protamine Hagedorn insulin 6.2%. From baseline to 6 months of treatment, no significant differences were found in the mean (SD) doses of glargine (30.8 \[16.8\] IU vs 31.9 \[17.1\] IU; *P* = 0.348) or detemir (44.5 \[32.6\] IU vs 50.8 \[27.3\] IU; *P* = 0.449), which represents just a slight increase in both cases. Regarding therapy with OADs, most patients were receiving biguanides (76%), followed by glinides (11.6%), and sulphonylureas (8.5%). Following 24 weeks of intensification therapy with lixisenatide, nonsignificant changes in the proportion of patients receiving these combinations were observed.

Safety {#sec0011}
------

Thirteen patients (10%) reported having experienced at least 1 ADR. Nausea was the most frequently reported ADR, with 12 patients (9.3%) experiencing at least 1 such event. One patient reported stomach disturbances and 1 patient reported hunger; hypoglycemia was rare, with 2 patients reporting an episode. No severe ADRs were reported during the study. [Table 3](#tbl0003){ref-type="table"} shows ADRs.Table 3Reported adverse drug reactions during the 6-month intensification therapy with lixisenatide and basal insulin.Table 3ReactionMildModerateTotalEn (%)En (%)En (%)Hypoglycaemia22 (1.6)00 (0.0)22 (1.6)Nausea44 (3.1)88 (6.2)1212 (9.3)Stomach disturbances11 (0.8)00 (0.0)11 (0.8)Hunger11 (0.8)00 (0.0)11 (0.8)Total88 (6.2)88 (6.2)1616 (12.4)[^6]

Discussion {#sec0012}
==========

The results of this study in this small, selected population suggest that intensification therapy with lixisenatide in combination with basal insulin (with or without OADs) when used in real-world clinical practice settings, is not only associated with an improvement in glycemic control, but also with significant reductions in FBG, PPG, and body weight at 24 weeks.

The decrease in HbA1c of 1.1% found, accompanied by achievements of optimal metabolic control (HbA1c ≤6.5% and ≤7%) and reduction of glucose levels, support a number of previous placebo-controlled clinical studies that demonstrated effective reductions in HbA1c and blood glucose levels when lixisenatide was administered once daily in combination with basal insulin.[@bib0008], [@bib0009], [@bib0010] In the GetGoal-Duo2 trial, Rosentock et al[@bib0011] reported comparable improvements of HbA1c levels (a decrease of 1.3%), as well as body weight reductions and lower incidence of hypoglycemia events in patients randomized to lixisenatide once daily added to glargine in comparison to those taking insulin glulisine once daily or 3 times daily. Similarly, the analysis of data from 5 randomized, controlled trials comparing addition of either insulin glulisine or lixisenatide to basal insulin showed that both combinations are effective in terms of HbA1c reductions, but patients being treated with lixisenatide presented lower risk of hypoglycemia and weight gain.[@bib0012] In an attempt to gain data on treatment with lixisenatide in real-life situations, a study published by Fleischmann et al[@bib0013] addressed the effectiveness of adding lixisenatide to basal insulin in patients with uncontrolled diabetes finding that following 6 months of treatment, a significant decrease in HbA1c level (0.94%; *P* ≤ 0.001) was achieved along with significant reductions in glucose levels and a marked decrease in the PPG excursions during the whole day. Similarly, findings from the study conducted by Roca-Rodríguez et al[@bib0014] to evaluate the effect of lixisenatide on metabolic control parameters and body weight in obese patients with type 2 diabetes concluded that lixisenatide was an effective treatment option in this group of patients, leading to similar HbA1c and FBG levels and body weight reductions in a real-world setting.

A well-known advantage of the addition of lixisenatide to basal insulin (with or without OADs) is the potential for weight loss. Indeed, following 24 weeks of intensification therapy with lixisenatide, we observed a large change in mean body weight (--4 kg), which may be explained by the higher baseline body weight of the patients included. This value is consistent with the value recorded in the aforementioned noninterventional observational study (3.1 \[4.1\] kg; *P* ≤ 0.001).[@bib0013] However, our value is higher than those reported in the clinical trials, with mean changes ranging from --1.3 kg (*P* \< 0.0001)[@bib0008] to the modest, albeit significant, --0.89 kg (*P* = 0.0012).[@bib0009]

Type 2 diabetes is a chronic metabolic disease commonly related to obesity that can lead to serious cardiovascular complications.[@bib0015] A recent systematic analysis comparing GLP-1 RAs to other glucose-lowering agents on cardiovascular risk factors showed favorable effects on systolic and diastolic blood pressure and total cholesterol levels, as well as a small but significant increase in heart rate.[@bib0016] The Evaluation of Lixisenatide in Acute Coronary Syndrome trial[@bib0017] assessed the effect of lixisenatide on cardiovascular outcomes in patients with type 2 diabetes who had had a recent acute coronary syndrome event, showing that the addition of lixisenatide to conventional therapy did not increase the risk of major cardiovascular events. Nonetheless, further prospective studies are required to study the long-term effect of intensification therapy with lixisenatide on cardiovascular events.

Gastrointestinal side effects are the most frequently reported adverse event with GLP-1 RAs and they are related to dose and background medication.[@bib0018] We found that \<10% of patients experienced gastrointestinal ADRs, nausea being the most commonly encountered event. This follows a similar pattern to that obtained in previous clinical studies,[@bib0008], [@bib0009] although with lower rates. The combination of basal insulin with a GLP-1 RA has gained significant interest these days, based on the complementary effects, the mitigating effect on body weight and hypoglycemia, and the reduction of gastrointestinal adverse effects in comparison when administered individually. The recently published results of the study led by Aroda et al[@bib0019] have shown that the delivery of a titratable fixed ratio combination of insulin glargine and lixisenatide appears to lessen the gastrointestinal intolerance typically associated with stepped titration of GLP-1 RAs while it confers advantages by simplifying and intensifying more efficiently basal insulin treatment in this group of patients.

Another benefit of the intensification therapy with lixisenatide is the low incidence of hypoglycemic events,[@bib0020] which were present in only 1.6% of patients, therefore confirming the findings obtained in controlled clinical trials. Patients with a long evolution of type 2 diabetes that have an insufficient glycemic control with previous therapies and that require insulin, will need another add-on agent such as GLP-1 RAs.[@bib0021] The advantages of a prandial/postprandial control with GLP-1 RAs instead of short-acting insulin taken during the main meals are that there is a lower risk of hypoglycemia, a body weight reduction,[@bib0022] and relief from the burden of frequent self-monitoring of blood glucose.[@bib0012]^,^[@bib0023], [@bib0024], [@bib0025]

In this study, we observed an improved glycemic control with significant reductions of postprandial excursions, weight control, and low rate of hypoglycemic events, although no patient satisfaction data were collected. A meta-analysis of the GetGoal program after 76 weeks of treatment shows that these beneficial effects in terms of glycemic control and weight reduction with a good safety profile are maintained with time[@bib0026] regardless of BMI category.[@bib0027]

There are some limitations to the study that should be considered when interpreting the results. Because this was an observational study, recording of hypoglycemic episodes and gastrointestinal side effects were self-reported by patients and collected retrospectively, leading perhaps to an underdiagnosis bias or failure to collect data. Similarly, the enthusiasm of starting a new treatment may lead patients to increase their physical activity and change their eating habits, therefore amplifying the observed effects. The absence of a control group means that the information extracted does not provide sufficient evidence to establish cause--effect relationships. Another limitation is the duration of the study---24 weeks---which is insufficient to determine clinical long-term benefits. However, the performance of this type of study is of the utmost relevance to determine the conditions derived from routine clinical practice.

Conclusions {#sec0013}
===========

The addition of short-acting lixisenatide to advance basal insulin therapy can be an effective treatment option in terms of glycemic control and body weight reduction with a low risk of hypoglycemia in patients with uncontrolled type 2 diabetes. These findings acquired in a real-world clinical setting support the evidence obtained from previous controlled clinical trials.
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[^1]: The BASAL-LIXI Study investigators are listed in the Acknowledgments.

[^2]: Value for male sex are presented as n (%); other values are presented as mean (SD).

[^3]: Missing data for n = 21 patients.

    ^‡^Missing data for n = 9 patients.

[^4]: Values for baseline and Week 24 are presented as mean (SD).

[^5]: Missing data for n = 9 and n = 7 patients at the initiation of therapy and Week 24, respectively.

[^6]: E = number of reactions.
